Study: Frequency of simultaneous application of CYP3A inhibitors

The objective of this study is the empirical investigation of the frequency of simultaneously applied CYP3A inhibitors in clinical routine. A retrospective and anonymized survey was chosen as the method. The analysis yielded the following results: 8.57% inpatient days (27 of 315) and 8.33% patients (4 of 48) were exposed to simultaneous application of CYP3A inhibitors. The frequency of simultaneously administered CYP3A inhibitors is strikingly high in patients diagnosed with AML, as an above-average number, namely 0.379 CYP3A inhibitors per day, were administered simultaneously. In comparison, NSCLC patients received only 0.053 and SCLC patients only 0.091 CYP3A inhibitors simultaneously per day.The suspicion that patients with AML are more likely to receive CYP3A inhibitors on inpatient days than all other patients was tested by the hypothesis test chi-square ( ²), Phi coefficient ( ) and Cramer's V index (CI) and was found to be significant.

Autorentext

Diana Isabella Dmytrow (*1984) is a clinical researcher (Master of Science) and health scientist/health manager (Bachelor of Science) and heads clinical research at Klinikum Frankfurt Höchst. Her main field of research is drug and disease research, primarily in cancer and stroke.